COMMUNIQUÉS West-GlobeNewswire

SoldierStrong, Gier Productions Announce Release of “The Heroism and Resiliency of 9/11” Documentary in 2026
09/09/2025
STAMFORD, Conn., Sept. 09, 2025 (GLOBE NEWSWIRE) -- SoldierStrong, a national nonprofit founded to help military veterans take their next steps forward in life, and award-winning director and producer Michael Gier today [...]
KFSHRC Deputy CEO at C3 Davos of Healthcare™ Summit: AI Will Support, Not Replace, Healthcare Workers
09/09/2025
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence is ready to play a major role in healthcare, but it must be seen as a tool to empower medical staff, not replace them, according to Dr. Björn Zoëga, [...]
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
09/09/2025
Results presented focus on clinical insights on Fabry disease and alpha-mannosidosis Additional presentations showcase patient-reported journeys and outcomes PARMA, Italy, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Chiesi [...]
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
09/09/2025
Results presented focus on clinical insights on Fabry disease and alpha-mannosidosis Additional presentations showcase patient-reported journeys and outcomes PARMA, Italy, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Chiesi [...]
Misophonia Research Fund to Host Impactful Conference on Misophonia: Bringing Together Science and Lived Experience to Create Solutions
09/09/2025
CHICAGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- On September 18, 2025, Chicago will be the site of a groundbreaking gathering focused on one of the most misunderstood sensory conditions: misophonia , a disorder in which [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2025
09/09/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 01 Septembre au 05 Septembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2025
09/09/2025
Aggregated presentation by day and by market Statement of transactions in own shares from 1 st September to 5 th September 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
Acesis Biomed Appoints Dr. Frederic Fasano, Pharm.D, MBA, ICD.D to the Board of Directors as Chairman
09/09/2025
CENTENNIAL, Colo., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Acesis Holdings Corporation (“Acesis Biomed”), a pre‑clinical stage biotechnology company pioneering oral treatments for metabolic and endocrine disorders linked to [...]
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
09/09/2025
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Breckenridge Brewery Awarded Silver Certification by the Colorado Green Business Network for Excellence in Sustainability Practices
09/09/2025
LITTLETON, Colo., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Breckenridge Brewery , a craft brewery owned by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), is proud to announce it has received the Silver [...]
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
09/09/2025
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade [...]
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
09/09/2025
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical- [...]
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
09/09/2025
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year [...]
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
09/09/2025
UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE [...]
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
09/09/2025
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- [...]
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
09/09/2025
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 ® , (Smallpox [...]
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
09/09/2025
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, [...]
MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors
09/09/2025
Betty Aldworth and Ismail Lourido Ali bring decades of combined experience in drug policy leadership, psychedelic advocacy, and movement building As Co-Executive Directors, Aldworth and Ali reflect MAPS' legacy [...]
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
09/09/2025
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine [...]

Pages